Tenon Medical Inc has filed a prospectus supplement to increase its at-the-market common stock offering capacity to approximately $7.18 million.

The filing, submitted to the Securities and Exchange Commission, details the amendment to the company's existing shelf registration statement. This action allows the medical device company to sell additional shares of its common stock through an at-the-market program.

Filing Details

The company updated its offering capacity via a 424B5 prospectus supplement. The total value of the increased offering is set at roughly $7.18 million. No other financial metrics or operational updates were disclosed in this specific regulatory submission.

Tenon Medical Inc. announced that the United States Patent and Trademark Office has issued 8 new patents to the company so far in fiscal year 2026. These additions reinforce the company's intellectual property portfolio in the sacro-pelvic fusion market.

With these recent grants, Tenon now holds 38 issued U.S. patents and 9 international patents. Additionally, the company has 31 patent applications pending across the United States and foreign jurisdictions. The newly issued patents encompass both strategic systems and method claims, providing underlying protection for the Catamaran SI Joint Fusion System.

Strengthening Market Position

The company states that these patents solidify its status as an innovator in the rapidly growing sacro-pelvic fusion sector. The intellectual property protections are designed to cover both the implant and the method of delivery, which Tenon believes creates barriers for competitors attempting to replicate the Catamaran procedure. This defensible IP position is viewed as critical for supporting physician adoption and long-term commercial strategy.

Richard Ginn, Chief Technology Officer, Chief Operations Officer and Director of Tenon, noted that the innovation process begins in the operating room. He stated that the eight new patents result directly from feedback provided by physicians and physician advisors, focusing engineering efforts on their guidance to drive procedure adoption.

Portfolio Overview

Tenon offers an integrated SI joint fusion portfolio with applications in SI joint fusion, spinal fusion, and deformity adjuncts. The current portfolio includes:

• Catamaran SI Joint Fusion System: A platform intended to redefine the standard of care in sacroiliac joint treatment using a single, robust titanium implant.
• SImmetry+ SI Joint Fusion System: Acquired in August 2025, this system offers a minimally invasive lateral access solution incorporating established orthopedic fusion principles.

What the Numbers Show

The data reveals a significant concentration of intellectual property assets relative to the company's operational footprint. With 38 issued U.S. patents and 31 pending applications, the total IP pipeline stands at 69 items. This suggests a strategic emphasis on building a dense protective moat around its core technology platforms before or during commercial expansion. The acquisition of SImmetry+ in August 2025 indicates that this IP accumulation strategy extends beyond organic development to include acquired assets, aiming to cover both the Catamaran and lateral access solutions comprehensively.